Trial Profile
Phase 2 Study of Brentuximab Vedotin Associated With CHP Followed by Consolidation With High-dose Therapy / Autologous Stem-cell Transplantation as Frontline Treatment of Patients With Enteropathy-associated T-cell Lymphoma Type 1
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Methylprednisolone; Prednisone
- Indications T-cell lymphoma
- Focus Therapeutic Use
- Acronyms EATL-001
- 11 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2021 first results of the EATL-001 trial presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 09 Feb 2021 Planned End Date changed from 1 Sep 2021 to 6 Feb 2024.